As previously reported, Needham analyst Mike Matson downgraded NuVasive (NUVA) to Underperform from Hold saying that his math indicates that consensus revenue estimates require an acceleration in its market share gains but NuVasive's rate of market share gain is more likely to decrease given the improving spine performance at Medtronic (MDT). Further, the analyst believes that slower revenue growth is likely to limit operating leverage putting consensus EPS estimates at risk as well. Matson expects NuVasive's revenue growth to approach the mid-single digits and its EPS growth to approach the mid-teens.